Historically, we immunized children against diseases like polio that were a clear danger to them, but COVID-19 is usually mild in children. However, herd immunity is unlikely without vaccinating kids.
Academic rigor, journalistic flair
Articles on Moderna
Displaying 1 - 20 of 24 articles
Rollout of COVID-19 vaccines has begun. But getting the jab doesn't mean abandoning masks, distancing and handwashing. Here's why the current preventive measures must continue post-vaccine.
Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it's better to give one dose to more people and give a second when the supply is better.
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can't support a cold supply chain.
With vaccines forthcoming for most Americans, many groups, including expectant mothers, are wondering if the vaccine is safe for them and their babies. A physician-scientist explains.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Millions of Americans say they won't get the vaccine. Will money change their minds? And is luring them with cash the right approach?
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand's.
Moderna's shot is far easier to store and distribute than Pfizer's. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here's how to fully interrogate what they mean.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here's where we stand on vaccine development, including positive results from Pfizer's trial.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Top contributors
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Professor of Medicine, University of Virginia
-
Professor of Immunology and Pro Vice-Chancellor, Research Partnerships, Victoria University
-
Professor of Law, Boston University
-
Assistant Professor of Law, Saint Louis University
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Senior Lecturer in Evidence-Based Healthcare and University Ethics Advisor, University of Portsmouth
-
Senior Lecturer in Public Management, Te Herenga Waka — Victoria University of Wellington
-
Part-time lecturer at the Global Health & Social Medicine, Harvard Medical School and lecturer at the School of Public Health, College of Health Sciences, University of Liberia
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Molecular and Cell Biology, University of California, Merced
-
Professor of Immunology, RMIT University
-
Associate Professor of Operations Management & Business Analytics, Johns Hopkins Carey Business School, Johns Hopkins University School of Nursing
-
Professor of Environmental Conservation, University of Massachusetts Amherst
-
Assistant Professor, Department of Pediatrics, Queen's University, Ontario
